LRMR
ACHAT TOTAL: 50000 titres (~166890 USD)
- Insiders
- Hamilton Thomas Edward
- Total bought
- $166,890
- Total sold
- —
- Last activity
- 2026-07-06
- Last synced
-
2026-08-04 10:23:03
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-03
LRMR presents a critically distressed financial profile with zero revenue, persistent operating losses, and negative cash flows, making the business model non-viable in its current state.
The first sentence of the analysis written for LRMR on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 2.192 | 8.019 | 9.486 | 11.279 | 8.162 | |
| Quick Ratio | 2.192 | 8.019 | 9.486 | 11.279 | 8.162 | |
| Solvency Ratio | -2.440 | -2.826 | -2.577 | -2.260 | -3.530 | |
| Cash Ratio | 1.318 | 1.364 | 2.814 | 2.506 | 7.924 | |
| Price To Earnings Ratio | -1.678 | -2.932 | -5.417 | -3.105 | -3.683 | |
| Price To Earnings Growth Ratio | -0.023 | -0.051 | 0.147 | 0.057 | 0.208 | |
| Forward Price To Earnings Growth Ratio | -0.023 | -0.051 | 0.147 | 0.057 | 0.208 | |
| Price To Earnings Diluted Ratio | -1.678 | -2.932 | -5.417 | -3.105 | -3.683 | |
| Price To Earnings Diluted Growth Ratio | -0.023 | -0.051 | 0.147 | 0.057 | 0.208 | |
| Price To Book Ratio | 3.559 | 1.380 | 2.444 | 0.959 | 2.875 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -2.453 | -3.326 | -5.941 | -3.845 | -4.364 | |
| Price To Operating Cash Flow Ratio | -2.455 | -3.350 | -5.970 | -3.859 | -4.399 | |
| Debt To Assets Ratio | 0.028 | 0.026 | 0.058 | 0.043 | 0.076 | |
| Debt To Equity Ratio | 0.052 | 0.030 | 0.068 | 0.049 | 0.093 | |
| Debt To Capital Ratio | 0.050 | 0.029 | 0.064 | 0.046 | 0.085 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.868 | 1.165 | 1.174 | 1.140 | 1.221 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -1.747 | -2.905 | -3.520 | -2.575 | -4.760 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.007 | 1.005 | 1.004 | 1.008 | |
| Debt Service Coverage Ratio | -149.614 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -102.444 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -27.834 | -13.828 | -6.033 | -5.098 | -7.015 | |
| Capital Expenditure Coverage Ratio | -1,243.967 | -137.398 | -204.020 | -275.690 | -126.441 | |
| Dividend Paid And Capex Coverage Ratio | -1,243.967 | -137.398 | -204.020 | -275.690 | -126.441 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.189 | -2.603 | -4.873 | -2.425 | -2.407 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 2.192 | ▼-5.827 | ▼-5.636 |
| Quick Ratio | 2.192 | ▼-5.827 | ▼-5.636 |
| Solvency Ratio | -2.440 | ▲0.386 | ▲0.287 |
| Cash Ratio | 1.318 | ▼-0.046 | ▼-1.867 |
| Price To Earnings Ratio | -1.678 | ▲1.253 | ▲1.685 |
| Price To Earnings Growth Ratio | -0.023 | ▲0.028 | ▼-0.091 |
| Forward Price To Earnings Growth Ratio | -0.023 | ▲0.028 | ▼-0.091 |
| Price To Earnings Diluted Ratio | -1.678 | ▲1.253 | ▲1.685 |
| Price To Earnings Diluted Growth Ratio | -0.023 | ▲0.028 | ▼-0.091 |
| Price To Book Ratio | 3.559 | ▲2.180 | ▲1.316 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -2.453 | ▲0.873 | ▲1.533 |
| Price To Operating Cash Flow Ratio | -2.455 | ▲0.895 | ▲1.551 |
| Debt To Assets Ratio | 0.028 | ▲0.002 | ▼-0.018 |
| Debt To Equity Ratio | 0.052 | ▲0.022 | ▼-0.006 |
| Debt To Capital Ratio | 0.050 | ▲0.021 | ▼-0.005 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.868 | ▲0.702 | ▲0.554 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -1.747 | ▲1.158 | ▲1.354 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.006 | ▼-0.004 |
| Debt Service Coverage Ratio | -149.614 | ▼-149.614 | ▼-119.691 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -102.444 | ▼-102.444 | ▼-81.956 |
| Operating Cash Flow Coverage Ratio | -27.834 | ▼-14.006 | ▼-15.872 |
| Capital Expenditure Coverage Ratio | -1243.967 | ▼-1106.569 | ▼-846.464 |
| Dividend Paid And Capex Coverage Ratio | -1243.967 | ▼-1106.569 | ▼-846.464 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.189 | ▲1.414 | ▲1.510 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $277.9M | $237.1M | $199.8M | $106.4M | $185.2M | |
| Enterprise value | $196.6M | $209.0M | $178.5M | $85.0M | $121.1M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -1.74x | -2.95x | -5.34x | -3.08x | -2.88x | |
| EV / Free cash flow | -1.74x | -2.93x | -5.31x | -3.07x | -2.85x | |
| EV / EBITDA | -1.19x | -2.60x | -4.87x | -2.42x | -2.41x | |
| Net debt / EBITDA | 0.49x | 0.35x | 0.58x | 0.61x | 1.27x | |
| Current ratio | 2.19x | 8.02x | 9.49x | 11.28x | 8.16x | |
| Income quality | 0.68x | 0.88x | 0.91x | 0.78x | 0.83x | |
| Graham net-net | $1 | $3 | $2 | $4 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $77.2M | $170.9M | $80.7M | $110.0M | $63.4M | |
| Invested capital | $79.9M | $174.7M | $84.4M | $113.7M | $67.8M | |
| Return on assets | -113.6% | -40.3% | -38.5% | -28.0% | -64.4% | |
| Operating ROA | -99.7% | -61.4% | -37.6% | -35.6% | -55.0% | |
| Return on tangible assets | -113.6% | -40.3% | -38.5% | -28.0% | -64.4% | |
| Return on equity | -212.2% | -46.9% | -45.2% | -31.9% | -78.6% | |
| Return on invested capital | -210.0% | -51.4% | -47.9% | -31.4% | -71.7% | |
| Return on capital employed | -212.8% | -51.7% | -48.3% | -31.6% | -72.3% | |
| Earnings yield | -59.6% | -34.0% | -18.5% | -33.2% | -27.3% | |
| Free cash flow yield | -40.8% | -30.1% | -16.8% | -26.0% | -22.9% | |
| Capex / Op. cash flow | -0.1% | -0.7% | -0.5% | -0.4% | -0.8% | |
| Capex / Depreciation | -6.8% | 161.9% | 52.7% | 31.4% | 102.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+17.2%EV / Sales n/aEV / EBITDA ▲+54.3%EV / Op. cash flow ▲+1.216Earnings yield ▼-0.256
Profitability
Return on equity ▼-1.653Return on assets ▼-0.733Return on invested capital ▼-1.586Return on capital employed ▼-1.612Operating ROA ▼-0.383Income quality ▼-0.195Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-5.827Net debt / EBITDA ▲+0.142Working capital ▼-93721000.000Invested capital ▼-94749000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+50.1%EV / Sales n/aEV / EBITDA ▲+50.6%EV / Op. cash flow ▲+1.140Earnings yield ▼-0.323
Profitability
Return on equity ▼-1.336Return on assets ▼-0.492Return on invested capital ▼-1.383Return on capital employed ▼-1.406Operating ROA ▼-0.446Income quality ▼-0.148Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-5.970Net debt / EBITDA ▼-0.782Working capital ▲+13869000.000Invested capital ▲+12105000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-23 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 2026-07-21 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 2026-07-16 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 2026-07-14 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 2026-07-09 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 2026-07-07 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 2026-07-01 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 2026-06-29 Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich''s Ataxia Transcript Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich''s Ataxia Transcript
- 2026-06-29 Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich''s Ataxia BALA CYNWYD, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced it has submitted the first module of its rolling Biologics License Application (BLA) submission to the Food and Drug Administration (FDA) for accelerated approval of nomlabofusp; the remaining modules are expected to be submitted in the second half of 2026. The submission was made after obtaining FDA meeting minutes of a Type B multidisciplinary pre-BLA meeting. The Company also announced positive data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp in adolescent and adult patients with Friedreich''s ataxia (FA). FA is a rare, progressive, and fatal neurological disease with no approved disease modifying therapies that address the root cause of the disease.
- 2026-06-26 Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich''s Ataxia BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company''s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich''s ataxia on Monday, June 29, 2026 at 7:45 am ET.